THOMAS A BUCHHOLZ to Neoplasm Recurrence, Local
This is a "connection" page, showing publications THOMAS A BUCHHOLZ has written about Neoplasm Recurrence, Local.
Connection Strength
3.398
-
Locoregional recurrence risk for patients with T1,2 breast cancer with 1-3 positive lymph nodes treated with mastectomy and systemic treatment. Int J Radiat Oncol Biol Phys. 2014 Jun 01; 89(2):392-8.
Score: 0.135
-
Hypofractionated breast radiation: preferred standard of care? Lancet Oncol. 2013 Oct; 14(11):1032-1034.
Score: 0.130
-
Radiation dose escalation for loco-regional recurrence of breast cancer after mastectomy. Radiat Oncol. 2013 Jan 11; 8:13.
Score: 0.124
-
Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer. Oncologist. 2011; 16(12):1675-83.
Score: 0.115
-
Radiotherapy and survival in breast cancer. Lancet. 2011 Nov 12; 378(9804):1680-2.
Score: 0.114
-
Estrogen/progesterone receptor negativity and HER2 positivity predict locoregional recurrence in patients with T1a,bN0 breast cancer. Int J Radiat Oncol Biol Phys. 2010 Aug 01; 77(5):1296-302.
Score: 0.103
-
Among women who experience a recurrence after postmastectomy radiation therapy irradiation is not associated with more aggressive local recurrence or reduced survival. Breast Cancer Res Treat. 2010 Sep; 123(2):597-605.
Score: 0.102
-
Ten-year recurrence rates in young women with breast cancer by locoregional treatment approach. Int J Radiat Oncol Biol Phys. 2009 Mar 01; 73(3):734-44.
Score: 0.091
-
Radiation use and long-term survival in breast cancer patients with T1, T2 primary tumors and one to three positive axillary lymph nodes. Int J Radiat Oncol Biol Phys. 2008 Jul 15; 71(4):1022-7.
Score: 0.088
-
The ratio of positive to excised nodes identifies high-risk subsets and reduces inter-institutional differences in locoregional recurrence risk estimates in breast cancer patients with 1-3 positive nodes: an analysis of prospective data from British Columbia and the M. D. Anderson Cancer Center. Int J Radiat Oncol Biol Phys. 2007 May 01; 68(1):59-65.
Score: 0.082
-
Comparison of risk of local-regional recurrence after mastectomy or breast conservation therapy for patients treated with neoadjuvant chemotherapy and radiation stratified according to a prognostic index score. Int J Radiat Oncol Biol Phys. 2006 Oct 01; 66(2):352-7.
Score: 0.079
-
The impact of young age on locoregional recurrence after doxorubicin-based breast conservation therapy in patients 40 years old or younger: How young is "young"? Int J Radiat Oncol Biol Phys. 2006 Aug 01; 65(5):1345-52.
Score: 0.078
-
In regard to post mastectomy radiotherapy. Int J Radiat Oncol Biol Phys. 2004 Oct 01; 60(2):686-7; author reply 687-8.
Score: 0.070
-
Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys. 2004 Aug 01; 59(5):1337-42.
Score: 0.069
-
Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. J Clin Oncol. 2004 Jun 15; 22(12):2303-12.
Score: 0.068
-
Positive surgical margins and ipsilateral breast tumor recurrence predict disease-specific survival after breast-conserving therapy. Cancer. 2003 Dec 01; 98(11):2522-3; author reply 2523-4.
Score: 0.066
-
Locoregional recurrence after doxorubicin-based chemotherapy and postmastectomy: Implications for breast cancer patients with early-stage disease and predictors for recurrence after postmastectomy radiation. Int J Radiat Oncol Biol Phys. 2003 Oct 01; 57(2):336-44.
Score: 0.065
-
Radiotherapy for early stage favourable breast cancers. Br J Cancer. 2002 Jan 21; 86(2):309-11.
Score: 0.058
-
Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation. J Clin Oncol. 2002 Jan 01; 20(1):17-23.
Score: 0.058
-
Impact of systemic treatment on local control for patients with lymph node-negative breast cancer treated with breast-conservation therapy. J Clin Oncol. 2001 Apr 15; 19(8):2240-6.
Score: 0.055
-
Increasing the value of radiotherapy in breast cancer. Lancet Oncol. 2021 05; 22(5):572-573.
Score: 0.055
-
Reply to A. Thomsen et al. J Clin Oncol. 2020 10 20; 38(30):3577.
Score: 0.053
-
Multidisciplinary Management of Locoregional Recurrent Breast Cancer. J Clin Oncol. 2020 07 10; 38(20):2321-2328.
Score: 0.052
-
Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer. JAMA Oncol. 2020 04 01; 6(4):505-511.
Score: 0.051
-
Importance of radiation therapy for breast cancer patients treated with high-dose chemotherapy and stem cell transplant. Int J Radiat Oncol Biol Phys. 2000 Jan 15; 46(2):337-43.
Score: 0.050
-
Impact of Radiation on Locoregional Control in Women with Node-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy and Axillary Lymph Node Dissection: Results from ACOSOG Z1071 Clinical Trial. Int J Radiat Oncol Biol Phys. 2019 09 01; 105(1):174-182.
Score: 0.048
-
Accelerated partial breast irradiation: Current status with a focus on clinical practice. Breast J. 2019 01; 25(1):124-128.
Score: 0.047
-
Outcomes of Post Mastectomy Radiation Therapy in Patients Receiving Axillary Lymph Node Dissection After Positive Sentinel Lymph Node Biopsy. Int J Radiat Oncol Biol Phys. 2016 11 01; 96(3):637-44.
Score: 0.040
-
Outcomes and predictive factors for salvage therapy after local--regional recurrence following neoadjuvant chemotherapy and breast conserving therapy. Ann Surg Oncol. 2013 Oct; 20(11):3430-7.
Score: 0.032
-
Evaluating locoregional recurrence in breast cancer. Int J Radiat Oncol Biol Phys. 2003 Mar 01; 55(3):850-1; author reply 851.
Score: 0.031
-
Impact of chemotherapy sequencing on local-regional failure risk in breast cancer patients undergoing breast-conserving therapy. Ann Surg. 2013 Feb; 257(2):173-9.
Score: 0.031
-
Factors associated with local-regional recurrence after a negative sentinel node dissection: results of the ACOSOG Z0010 trial. Ann Surg. 2012 Sep; 256(3):428-36.
Score: 0.030
-
Impact of internal mammary lymph node drainage identified by preoperative lymphoscintigraphy on outcomes in patients with stage I to III breast cancer. Cancer. 2012 Dec 15; 118(24):6287-96.
Score: 0.030
-
Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy. Breast Cancer Res. 2012 May 23; 14(3):R82.
Score: 0.030
-
Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy. Breast Cancer Res. 2012 May 23; 14(3):R83.
Score: 0.030
-
Centromere protein-A, an essential centromere protein, is a prognostic marker for relapse in estrogen receptor-positive breast cancer. Breast Cancer Res. 2012 May 04; 14(3):R72.
Score: 0.030
-
Hormone receptor status influences the locoregional benefit of trastuzumab in patients with nonmetastatic breast cancer. Cancer. 2012 Oct 15; 118(20):4936-43.
Score: 0.029
-
Hazard of recurrence among women after primary breast cancer treatment--a 10-year follow-up using data from SEER-Medicare. Cancer Epidemiol Biomarkers Prev. 2012 May; 21(5):800-9.
Score: 0.029
-
Local-regional recurrence with and without radiation therapy after neoadjuvant chemotherapy and mastectomy for clinically staged T3N0 breast cancer. Int J Radiat Oncol Biol Phys. 2011 Nov 01; 81(3):782-7.
Score: 0.028
-
Evaluation of the MD Anderson Prognostic Index for local-regional recurrence after breast conserving therapy in patients receiving neoadjuvant chemotherapy. Ann Surg Oncol. 2012 Mar; 19(3):901-7.
Score: 0.028
-
A multidisciplinary protocol for planned skin-preserving delayed breast reconstruction for patients with locally advanced breast cancer requiring postmastectomy radiation therapy: 3-year follow-up. Plast Reconstr Surg. 2011 Jun; 127(6):2154-2166.
Score: 0.028
-
Classification of ipsilateral breast tumor recurrences after breast conservation therapy can predict patient prognosis and facilitate treatment planning. Ann Surg. 2011 Mar; 253(3):572-9.
Score: 0.027
-
The impact of age on outcome in early-stage breast cancer. Semin Radiat Oncol. 2011 Jan; 21(1):26-34.
Score: 0.027
-
Long-term outcomes in patients with isolated supraclavicular nodal recurrence after mastectomy and doxorubicin-based chemotherapy for breast cancer. Int J Radiat Oncol Biol Phys. 2011 Aug 01; 80(5):1453-7.
Score: 0.027
-
Patients with only 1 positive hormone receptor have increased locoregional recurrence compared with patients with estrogen receptor-positive progesterone receptor-positive disease in very early stage breast cancer. Cancer. 2011 Apr 15; 117(8):1595-601.
Score: 0.027
-
Intraoperative radiotherapy for early breast cancer. Lancet. 2010 Oct 02; 376(9747):1141; author reply 1143-4.
Score: 0.026
-
Present-day locoregional control in patients with t1 or t2 breast cancer with 0 and 1 to 3 positive lymph nodes after mastectomy without radiotherapy. Ann Surg Oncol. 2010 Nov; 17(11):2899-908.
Score: 0.026
-
Low locoregional recurrence rates in patients treated after 2000 with doxorubicin based chemotherapy, modified radical mastectomy, and post-mastectomy radiation. Radiother Oncol. 2010 Jun; 95(3):312-6.
Score: 0.025
-
Molecular predictors of locoregional recurrence in breast cancer: ready for prime time? J Clin Oncol. 2010 Apr 01; 28(10):1627-9.
Score: 0.025
-
DEAR1 is a dominant regulator of acinar morphogenesis and an independent predictor of local recurrence-free survival in early-onset breast cancer. PLoS Med. 2009 May 26; 6(5):e1000068.
Score: 0.024
-
Radiation therapy for early-stage breast cancer after breast-conserving surgery. N Engl J Med. 2009 Jan 01; 360(1):63-70.
Score: 0.023
-
Locoregional treatment outcomes after multimodality management of inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 2008 Oct 01; 72(2):474-84.
Score: 0.022
-
Placement of radiopaque clips for tumor localization in patients undergoing neoadjuvant chemotherapy and breast conservation therapy. Cancer. 2007 Dec 01; 110(11):2420-7.
Score: 0.022
-
Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease. Cancer. 2007 Oct 01; 110(7):1436-44.
Score: 0.021
-
Effect of postmastectomy radiotherapy in patients <35 years old with stage II-III breast cancer treated with doxorubicin-based neoadjuvant chemotherapy and mastectomy. Int J Radiat Oncol Biol Phys. 2007 Dec 01; 69(5):1478-83.
Score: 0.021
-
Should all patients undergoing breast conserving therapy for DCIS receive radiation therapy? Yes. Radiation therapy, an important component of breast conserving treatment for patients with ductal carcinoma in situ of the breast. J Surg Oncol. 2007 Jun 15; 95(8):610-3.
Score: 0.021
-
Effectiveness of radiation therapy in older women with ductal carcinoma in situ. J Natl Cancer Inst. 2006 Sep 20; 98(18):1302-10.
Score: 0.020
-
Low local recurrence rate without postmastectomy radiation in node-negative breast cancer patients with tumors 5 cm and larger. Int J Radiat Oncol Biol Phys. 2006 Oct 01; 66(2):358-64.
Score: 0.020
-
Fifteen-year results of a randomized prospective trial of hyperfractionated chest wall irradiation versus once-daily chest wall irradiation after chemotherapy and mastectomy for patients with locally advanced noninflammatory breast cancer. Int J Radiat Oncol Biol Phys. 2006 Jul 15; 65(4):1155-60.
Score: 0.020
-
Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy. Cancer. 2006 Jan 01; 106(1):42-50.
Score: 0.019
-
Predictors of systemic recurrence and disease-specific survival after ipsilateral breast tumor recurrence. Cancer. 2005 Aug 01; 104(3):479-90.
Score: 0.018
-
Improving local control with breast-conserving therapy: a 27-year single-institution experience. Cancer. 2005 Jul 01; 104(1):20-9.
Score: 0.018
-
Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys. 2005 Jun 01; 62(2):351-7.
Score: 0.018
-
Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst. 2005 Mar 16; 97(6):419-24.
Score: 0.018
-
Breast conservation after neoadjuvant chemotherapy. Cancer. 2005 Feb 15; 103(4):689-95.
Score: 0.018
-
T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy. Int J Radiat Oncol Biol Phys. 2004 May 01; 59(1):138-45.
Score: 0.017
-
Treatment and outcome of patients with chest wall recurrence after mastectomy and breast reconstruction. Am J Surg. 2004 Feb; 187(2):164-9.
Score: 0.017
-
Chest wall recurrence after mastectomy does not always portend a dismal outcome. Ann Surg Oncol. 2003 Jul; 10(6):628-34.
Score: 0.016
-
Classifying local disease recurrences after breast conservation therapy based on location and histology: new primary tumors have more favorable outcomes than true local disease recurrences. Cancer. 2002 Nov 15; 95(10):2059-67.
Score: 0.015
-
Predictors of locoregional recurrence among patients with early-stage breast cancer treated with breast-conserving therapy. Ann Surg Oncol. 2002 Apr; 9(3):256-65.
Score: 0.015
-
Controversies regarding the use of radiation after mastectomy in breast cancer. Oncologist. 2002; 7(6):539-46.
Score: 0.014
-
Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy. Cancer J. 2001 Sep-Oct; 7(5):413-20.
Score: 0.014
-
Local-regional control in breast cancer patients with a possible genetic predisposition. Int J Radiat Oncol Biol Phys. 2000 Nov 01; 48(4):951-7.
Score: 0.013
-
Presentation, management and outcome of axillary recurrence from breast cancer. Am J Surg. 2000 Oct; 180(4):252-6.
Score: 0.013
-
Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation. J Clin Oncol. 2000 Aug; 18(15):2817-27.
Score: 0.013
-
Local-regional control of recurrent breast carcinoma after mastectomy: does hyperfractionated accelerated radiotherapy improve local control? Int J Radiat Oncol Biol Phys. 1999 Apr 01; 44(1):105-12.
Score: 0.012
-
Outcomes of Curative-Intent Treatment for Patients With Breast Cancer Presenting With Sternal or Mediastinal Involvement. Int J Radiat Oncol Biol Phys. 2019 07 01; 104(3):574-581.
Score: 0.012
-
Cost-effectiveness of posttreatment surveillance after radiation therapy for early stage seminoma. Cancer. 1998 Mar 15; 82(6):1126-33.
Score: 0.011
-
Multidisciplinary international survey of post-operative radiation therapy practices after nipple-sparing or skin-sparing mastectomy. Eur J Surg Oncol. 2017 Nov; 43(11):2036-2043.
Score: 0.011
-
A phase 2 study of capecitabine and concomitant radiation in women with advanced breast cancer. Int J Radiat Oncol Biol Phys. 2017 11 15; 99(4):777-783.
Score: 0.010
-
Postoperative Radiation Therapy after Nipple-Sparing or Skin-Sparing Mastectomy: A Survey of European, North American, and South American Practices. Breast J. 2017 Jan; 23(1):26-33.
Score: 0.010
-
Defining the value framework for prostate brachytherapy using patient-centered outcome metrics and time-driven activity-based costing. Brachytherapy. 2016 May-Jun; 15(3):274-282.
Score: 0.010
-
Simvastatin radiosensitizes differentiated and stem-like breast cancer cell lines and is associated with improved local control in inflammatory breast cancer patients treated with postmastectomy radiation. Stem Cells Transl Med. 2014 Jul; 3(7):849-56.
Score: 0.009
-
Breast cancer multifocality and multicentricity and locoregional recurrence. Oncologist. 2013; 18(11):1167-73.
Score: 0.008
-
Neutron radiotherapy for adenoid cystic carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 1993 Jul; 119(7):747-52.
Score: 0.008
-
Effect of delay in radiation in the combined modality treatment of breast cancer. Int J Radiat Oncol Biol Phys. 1993 Apr 30; 26(1):23-35.
Score: 0.008
-
Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer. Ann Oncol. 2013 Aug; 24(8):1999-2004.
Score: 0.008
-
High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol. 2009 Dec 01; 27(34):5700-6.
Score: 0.006
-
The impact of pregnancy on breast cancer outcomes in women
View in: PubMed
Score: 0.006
Completion of adjuvant radiation therapy among women with breast cancer. Cancer. 2008 Jul 01; 113(1):22-9.
Score: 0.006
Practical guidelines for repair of partial mastectomy defects using the breast reduction technique in patients undergoing breast conservation therapy. Plast Reconstr Surg. 2007 Dec; 120(7):1755-1768.
Score: 0.005
Squamous cell carcinoma of the breast. J Clin Oncol. 2005 Nov 01; 23(31):7827-35.
Score: 0.005
Clinical investigation: regional nodal failure patterns in breast cancer patients treated with mastectomy without radiotherapy. Int J Radiat Oncol Biol Phys. 2005 Dec 01; 63(5):1508-13.
Score: 0.005
Paget's disease of the breast: there is a role for breast-conserving therapy. Ann Surg Oncol. 2005 May; 12(5):391-7.
Score: 0.005
The biologic rationale for and emerging role of accelerated partial breast irradiation for breast cancer. J Am Coll Surg. 2004 Sep; 199(3):479-92.
Score: 0.004
Effective local control and long-term survival in patients with T4 locally advanced breast cancer treated with breast conservation therapy. Ann Surg Oncol. 2004 Sep; 11(9):854-60.
Score: 0.004
Positive surgical margins and ipsilateral breast tumor recurrence predict disease-specific survival after breast-conserving therapy. Cancer. 2003 Feb 15; 97(4):926-33.
Score: 0.004
Breast-conservation therapy in early-stage breast cancer patients with a positive family history. Ann Surg Oncol. 2002 Nov; 9(9):912-9.
Score: 0.004
Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma. Am J Surg. 2001 Dec; 182(6):601-8.
Score: 0.004
Feasibility of breast preservation in the treatment of occult primary carcinoma presenting with axillary metastases. Ann Surg Oncol. 2001 Jun; 8(5):425-31.
Score: 0.003
Ductal carcinoma-in-situ: long-term results of breast-conserving therapy. Ann Surg Oncol. 2000 Oct; 7(9):656-64.
Score: 0.003
Feasibility of breast conservation therapy in metachronous or synchronous bilateral breast cancer. Ann Surg Oncol. 1999 Jan-Feb; 6(1):102-8.
Score: 0.003